bluebird bio to split into oncology and gene therapy special...

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning off as the company prepares to bring its products to market.

Bluebird trumpets long-term data from beta-thalassaemia gene...

bluebird bio has presented long-term data from its Zynteglo one-time gene therapy for the blood disorder beta-thalassaemia, as the company continues talks with payers in Europe to bring the

EMA starts rapid review of Bluebird’s gene therapy for rare ...

Bluebird bio could be just a few months away from approval of its gene therapy for rare disease cerebral adrenoleukodystrophy (CALD) in the EU, after the EMA started an accelerated review.<

BMS 'bet' with Celgene shareholders in balance after CAR-T r...

Bristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a three drug “bet” with former Celgene shareholders dependent on a fast r

BMS' big merger bet is still on with latest CAR-T filing

Bristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final part of a three-drug “bet” that was a sweetener following its $74 b

LentiGlobin gene therapy for sickle cell on course for filin...